Sodium hexacyanocobaltate.hydrat | CAS:14039-23-7

We serve Sodium hexacyanocobaltate.hydrat CAS:14039-23-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Sodium hexacyanocobaltate.hydrat

Chemical Name:Sodium hexacyanocobaltate.hydrat
CAS.NO: 14039-23-7
Molecular Formula:C6CoN6Na3
Molecular Weight: 284.00700
 
Synonyms:
Sodium hexacyanocobaltate.hydrat
Sodium cobaltic cyanide
EINECS 237-879-7
Trisodium hexacyanocobaltate
cobalt(3+) sodium cyanide(1:3:6)
trisodium cobalt(3+) hexacyanide
 
Physical and Chemical Properties:
Boiling point: 25.7ºC at 760mmHg
 
 
Specification:
Appearance: Light yellow crystal powder
Purity: ≥98%
Free cyanide,:≤0.01%
Fe,:≤0.0005%
SO4,:≤0.02%
Water insoluble subatance :≤0.001%
Alkalinity ,meq/g:≤0.15
 
Packing:N.W.25kg/carton drum with plastic lining bag
Storage:Sealed in a cool and dry environment.
Application:the main raw material of double metal catalyst, plating material for diamagnetic alloy



Contact us for information like Calcium formate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,trisodium cobalt(3+) hexacyanide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole,hydrochloride Use and application,2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline Hydrochloride technical grade,usp/ep/jp grade.


Related News: Prime Minister Scott Morrison said Saturday that all travelers from mainland China allowed into Australia had to be quarantined for 14 days.2-(7-Methoxynaphthalen-1-yl)Acetic Acid manufacturer Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.ethyl 4-methoxy-3-oxobutanoate supplier Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.5-Chloro-2-hydroxypyridine vendor There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space.